Soleno Therapeutics (SLNO) EBIT (2016 - 2017)
Historic EBIT for Soleno Therapeutics (SLNO) over the last 5 years, with Q4 2017 value amounting to -$5.2 million.
- Soleno Therapeutics' EBIT fell 18361.53% to -$5.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$12.2 million, marking a year-over-year decrease of 1749.07%. This contributed to the annual value of -$187.7 million for FY2024, which is 35348.69% down from last year.
- Per Soleno Therapeutics' latest filing, its EBIT stood at -$5.2 million for Q4 2017, which was down 18361.53% from -$2.6 million recorded in Q3 2017.
- Over the past 5 years, Soleno Therapeutics' EBIT peaked at -$559783.0 during Q4 2013, and registered a low of -$5.2 million during Q4 2017.
- Its 5-year average for EBIT is -$2.3 million, with a median of -$2.1 million in 2016.
- As far as peak fluctuations go, Soleno Therapeutics' EBIT tumbled by 25467.84% in 2015, and later soared by 6779.26% in 2017.
- Over the past 5 years, Soleno Therapeutics' EBIT (Quarter) stood at -$559783.0 in 2013, then tumbled by 229.72% to -$1.8 million in 2014, then tumbled by 89.99% to -$3.5 million in 2015, then surged by 47.73% to -$1.8 million in 2016, then crashed by 183.62% to -$5.2 million in 2017.
- Its EBIT stands at -$5.2 million for Q4 2017, versus -$2.6 million for Q3 2017 and -$3.0 million for Q2 2017.